Cardiovascular safety of non-steroidal anti-inflammatory drugs in chronic inflammatory rheumatic diseases

被引：5
作者：
Zavodovsky, B. V. [1 ]
Sivordova, L. E. [1 ]
机构：
[1] AB Zborovsky Res Inst Clin & Expt Rheumatol, Volgograd, Russia
来源：
TERAPEVTICHESKII ARKHIV | 2018年 / 90卷 / 08期
关键词：
cardiovascular diseases; cardiovascular risk; rheumatic diseases; rheumatoid arthritis; systemic lupus erythematosus; psoriatic arthritis; ankylosing spondylitis; chronic inflammation; non-steroidal anti-inflammatory drugs; ANKYLOSING-SPONDYLITIS; MYOCARDIAL-INFARCTION; COX-2; INHIBITORS; RISK-MANAGEMENT; ARTHRITIS; ETORICOXIB; MORTALITY; EVENTS; CELECOXIB; NAPROXEN;
D O I：
10.26442/terarkh2018908101-106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rheumatic diseases (RD), such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, vasculitis, gout are associated with increase in cardiovascular morbidity and mortality. The main causes of increased cardiovascular risk are inflammatory heart and vascular lesions, accelerated progression of atherosclerosis and side effects of drug therapy. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in clinical practice and are on the list of the most prescribed medications. It is known that NSAIDs have a negative effect on the cardiovascular system (CVS). However NSAIDs may decrease the intensity of inflammation, which is an independent risk risk factor for CVS pathology. Therefore in patients with RD it is theoretically possible to reduce the severity of cardiovascular side effects when using NSAIDs. The article discusses the issues of NSAID's cardiovascular safety, the molecular mechanisms underlying the negative effect of them on CVS, critically evaluated the results of main studies concerning the cardiovascular safety of NSAIDs in chronic inflammatory diseases.
引用
收藏
页码：101 / 106
页数：6
相关论文
共 65 条
  • [31] Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the standard care versus celecoxib outcome trial (SCOT)
    MacDonald, Thomas M.
    Mackenzie, Isla S.
    Wei, Li
    Hawkey, Christopher J.
    Ford, Ian
    [J]. BMJ OPEN, 2013, 3 (01):
  • [32] Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease Anti-inflammatory Prevention Trial (ADAPT)
    Martin, Barbara K.
    Breitner, John C. S.
    Evans, Denis
    Lyketsos, Constantine G.
    Meinert, Curtis L.
    [J]. PLOS CLINICAL TRIALS, 2006, 1 (07):
  • [33] Mavrogeni Sophie, 2009, Inflammation & Allergy Drug Targets, V8, P390
  • [34] [Насонов Е.Л. Nasonov E.L.], 2017, [Научно-практическая ревматология, Rheumatology Science and Practice, Nauchno-prakticheskaya revmatologiya], V55, P457, DOI 10.14412/1995-4484-2017-457-459
  • [35] Nasonov EL., 2008, ANTIFOSFOLIPIDNYI SI
  • [36] Nasonov EL, 2017, ROSSIJSKIJ ZH GASTRO, V27, P69, DOI [10.22416/1382-4376-2017-27-5-69-75, DOI 10.22416/1382-4376-2017-27-5-69-75]
  • [37] The risk of congestive heart failure in rheumatoid arthritis - A population-based study over 46 years
    Nicola, PJ
    Maradit-Kremers, H
    Roger, VL
    Jacobsen, SJ
    Crowson, CS
    Ballman, KV
    Gabriel, SE
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 412 - 420
  • [38] Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
    Nissen, Steven E.
    Yeomans, Neville D.
    Solomon, Daniel H.
    Luescher, Thomas F.
    Libby, Peter
    Husni, M. Elaine
    Graham, David Y.
    Borer, Jeffrey S.
    Wisniewski, Lisa M.
    Wolski, Katherine E.
    Wang, Qiuqing
    Menon, Venu
    Ruschitzka, Frank
    Gaffney, Michael
    Beckerman, Bruce
    Berger, Manuela F.
    Bao, Weihang
    Lincoff, A. Michael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) : 2519 - 2529
  • [39] Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery
    Nussmeier, NA
    Whelton, AA
    Brown, MT
    Langford, RM
    Hoeft, A
    Parlow, JL
    Boyce, SW
    Verburg, KM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1081 - 1091
  • [40] Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
    Ogdie, Alexis
    Yu, YiDing
    Haynes, Kevin
    Love, Thorvardur Jon
    Maliha, Samantha
    Jiang, Yihui
    Troxel, Andrea B.
    Hennessy, Sean
    Kimmel, Steven E.
    Margolis, David J.
    Choi, Hyon
    Mehta, Nehal N.
    Gelfand, Joel M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 326 - 332
1234567